<DOC>
	<DOCNO>NCT02324985</DOCNO>
	<brief_summary>This study design evaluate analgesic safety efficacy study drug ( AP0302 ) apply topically every 6 hour compare vehicle , subject experience delay onset muscle soreness .</brief_summary>
	<brief_title>Phase II Study AP0302 5 % Versus Vehicle Comparator</brief_title>
	<detailed_description>The purpose study evaluate efficacy safety S-Ibuprofen Topical Gel 5 % reduce pain/soreness associate delayed onset muscle soreness ( DOMS ) .</detailed_description>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>clinically significant medical condition BMI 1830 negative drug , alcohol , pregnancy screen protocoldefined inclusion criterion may apply upper extremity workout last 6 month job require heavy lift history muscle disorder allergy intolerance study drug history recent pain medication use protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>muscle soreness</keyword>
</DOC>